TY - JOUR
T1 - Pregnane X receptor activation triggers rapid ATP release in primed macrophages that mediates NLRP3 inflammasome activation
AU - Hudson, Grace
AU - Flannigan, Kyle L.
AU - Venu, Vivek Krishna Pulakazhi
AU - Alston, Laurie
AU - Sandall, Christina F.
AU - MacDonald, Justin A.
AU - Muruve, Daniel A.
AU - Chang, Thomas K.H.
AU - Mani, Sridhar
AU - Hirota, Simon A.
N1 - Funding Information:
S.A.H.'s salary is supported by the Canadian Institutes of Health Research's (CIHR) Canada Research Chair (CRC) program [Tier II CRC in Host-Microbe Interactions and Chronic Disease]. S.A.H.'s laboratory is supported by an infrastructure grant provided by the Canadian Foundation for Innovation John R. Evans Leaders Fund; operating funds from Crohn's & Colitis Canada (S.A.H. and T.K.H.C. coinvestigators); the Dr. Lloyd Sutherland Investigatorship in IBD/GI Research; and Natural Sciences and Engineering Research Council (NSERC) Discovery Grant [RGPIN-2016-03842]. S.M.'s laboratory is supported by National Institutes of Health [Grants CA161879 and CA222469], U.S. Department of Defense [W81XWH-17-1-0479], and Broad Medical Research Program-Crohn's & Colitis Foundation Investigator Award [Proposal 262520]. J.A.M. and D.A.M. are supported by the CIHR Health Challenges in Chronic Disease Signature Initiative [THC-13523]. C.F.S. holds scholarship awards from the Natural Sciences and Engineering Research Council and the Cumming School of Medicine. K.L.F. received support from the Beverly Philips postdoctoral fellowship through the Snyder Institute for Chronic Diseases at the University of Calgary and is currently supported by postdoctoral fellowships from Alberta Innovates and the Canadian Association of Gastroenterology/CIHR/Abbvie. T.K.H.C.'s laboratory is supported by a NSERC Discovery Grant [RPGIN-2014-03734].
Funding Information:
S.A.H.’s salary is supported by the Canadian Institutes of Health Research’s (CIHR) Canada Research Chair (CRC) program [Tier II CRC in Host–Microbe Interactions and Chronic Disease]. S.A.H.’s laboratory is supported by an infrastructure grant provided by the Canadian Foundation for Innovation John R. Evans Leaders Fund; operating funds from Crohn’s & Colitis Canada (S.A.H. and T.K.H.C. coinvestigators); the Dr. Lloyd Sutherland Investigator-ship in IBD/GI Research; and Natural Sciences and Engineering Research Council (NSERC) Discovery Grant [RGPIN-2016-03842]. S.M.’s laboratory is supported by National Institutes of Health [Grants CA161879 and CA222469], U.S. Department of Defense [W81XWH-17-1-0479], and Broad Medical Research Program–Crohn’s & Colitis Foundation Investigator Award [Proposal 262520]. J.A.M. and D.A.M. are supported by the CIHR Health Challenges in Chronic Disease Signature Initiative [THC-13523]. C.F.S. holds scholarship awards from the Natural Sciences and Engineering Research Council and the Cumming School of Medicine. K.L.F. received support from the Beverly Philips postdoctoral fellowship through the Snyder Institute for Chronic Diseases at the University of Calgary and is currently supported by postdoctoral fellowships from Alberta Innovates and the Canadian Association of Gastroenterology/CIHR/Abbvie. T.K.H.C.’s laboratory is supported by a NSERC Discovery Grant [RPGIN-2014-03734]. The authors declare no competing or commercial interests. https://doi.org/10.1124/jpet.118.255679. s This article has supplemental material available at jpet.aspetjournals.org.
Publisher Copyright:
© 2019 by The American Society for Pharmacology and Experimental Therapeutics.
PY - 2019
Y1 - 2019
N2 - The pregnane X receptor (PXR) is a ligand-activated nuclear receptor that acts as a xenobiotic sensor, responding to compounds of foreign origin, including pharmaceutical compounds, environmental contaminants, and natural products, to induce transcriptional events that regulate drug detoxification and efflux pathways. As such, the PXR is thought to play a key role in protecting the host from xenobiotic exposure. More recently, the PXR has been reported to regulate the expression of innate immune receptors in the intestine and modulate inflammasome activation in the vasculature. In the current study, we report that activation of the PXR in primed macrophages triggers caspase-1 activation and interleukin-1b release. Mechanistically, we show that this response is nucleotide-binding oligomerization domain, leucine-rich repeat, and pyrin domain-containing 3-dependent and is driven by the rapid efflux of ATP and P2X purinoceptor 7 activation following PXR stimulation, an event that involves pannexin-1 gating, and is sensitive to inhibition of Src-family kinases. Our findings identify a mechanism whereby the PXR drives innate immune signaling, providing a potential link between xenobiotic exposure and the induction of innate inflammatory responses.
AB - The pregnane X receptor (PXR) is a ligand-activated nuclear receptor that acts as a xenobiotic sensor, responding to compounds of foreign origin, including pharmaceutical compounds, environmental contaminants, and natural products, to induce transcriptional events that regulate drug detoxification and efflux pathways. As such, the PXR is thought to play a key role in protecting the host from xenobiotic exposure. More recently, the PXR has been reported to regulate the expression of innate immune receptors in the intestine and modulate inflammasome activation in the vasculature. In the current study, we report that activation of the PXR in primed macrophages triggers caspase-1 activation and interleukin-1b release. Mechanistically, we show that this response is nucleotide-binding oligomerization domain, leucine-rich repeat, and pyrin domain-containing 3-dependent and is driven by the rapid efflux of ATP and P2X purinoceptor 7 activation following PXR stimulation, an event that involves pannexin-1 gating, and is sensitive to inhibition of Src-family kinases. Our findings identify a mechanism whereby the PXR drives innate immune signaling, providing a potential link between xenobiotic exposure and the induction of innate inflammatory responses.
UR - http://www.scopus.com/inward/record.url?scp=85067268607&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067268607&partnerID=8YFLogxK
U2 - 10.1124/jpet.118.255679
DO - 10.1124/jpet.118.255679
M3 - Article
C2 - 31004077
AN - SCOPUS:85067268607
SN - 0022-3565
VL - 370
SP - 44
EP - 53
JO - Journal of Pharmacology and Experimental Therapeutics
JF - Journal of Pharmacology and Experimental Therapeutics
IS - 1
ER -